Organisation paid for research Program year 2025 Source: CMS Open Payments

Revival Research Corporation

Neither a doctor nor a teaching hospital

Research payments

$524,631

131 payments

Through program year 2025, Revival Research Corporation is reported as receiving $524,631 in research payments, across 131 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $31,947 13
2024 Research $113,510 52
2023 Research $90,017 19
2022 Research $36,979 8
2021 Research $44,133 11
2020 Research $130,271 14
2019 Research $77,775 14

Breakdown

Who paid Research payments · program years 2019–2025
  1. AbbVie, Inc. $289,159 61 payments
  2. Abbott Laboratories $129,616 43 payments
  3. Chiesi USA, Inc. $47,302 13 payments
  4. Pfizer Inc. $40,341 11 payments
  5. Taro Pharmaceuticals USA, Inc. $18,000 2 payments
  6. Galderma Laboratories, L.P. $214 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. M18-891 $138,051 14 payments
  2. A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) $45,498 15 payments
  3. FreeStyle Libre Pro Flash Glucose Monitoring System Type 2 Basal Plus Study $45,105 3 payments
  4. A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) $43,204 13 payments
  5. A Phase 2 Randomized Doubleblind Placebocontrolled Study to Investigate the Efficacy and Safety of Pf07275315 and Pf07264660 in Adult Participants With Moderatesevere Atopic Dermatitis $40,341 11 payments
  6. Abbott Sensor Based Monitoring System Multiple Analyte Characterization Study Using Venous and/or Capillary Reference $35,571 24 payments
  7. A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis $34,133 10 payments
  8. A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (Triton) $26,869 7 payments
  9. FreeStyle Libre Pro Flash Glucose Monitoring System Type2 Basal Plus Study $24,890 11 payments
  10. T2 FSL2 Weight Loss $24,050 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record